Dipneo Opens a Round through Capital Cell to Raise 300,000 Euros

The start-up Dipneo, created by the Eurecat technology centre and Mobile World Capital Barcelona, ​​has launched an investment campaign through the crowdfunding platform specialising in biotechnology and health, Capital Cell. The capital increase aims to raise 300,000 euros to speed up the development of an innovative medical device in the field of cardiorespiratory resuscitation .

Valued at 2.4 million euros, Dipneo will use the funds raised during the campaign to finalise the commercial prototype and initiate regulatory procedures in order to bring the new device to market, which differs from the airbag-based insufflators currently available in that it operates autonomously and hands-free.

The new Dipneo device is based on a system patented by Eurecat that allows air to be inflated into the patient autonomously, a feature that makes it optimal for non-expert users, as well as professionals. According to Dipneo CEO Xavier Castells, “Dipneo’s goal is to bring the first version of the medical device to market in 2026,” with sales forecast to reach 2.5 million euros in 2027 .

Dipneo aims to position itself as a complement in the defibrillator market

The company’s goal is “to be the perfect complement to defibrillators, known as AEDs, with a market potential of 4.2 billion euros and expected growth of 8.8 percent per year ” said Dipneo’s technology director, biomedical engineer Julio Díaz.

Dipneo “will have an impact in extra-hospital environments such as medical emergencies, in-hospital environments such as primary care centres, emergencies and traffic rescues, but also in cardioprotected areas, such as retirement homes, companies, sports facilities and municipal facilities, among others,” explained the company’s co-founder and head of the valorisation of industrial technologies at Eurecat, Ferran Soldevila.

Out-of-hospital cardiopulmonary arrests are estimated to occur at 700,000 per year in Europe and represent a serious health problem , given that the survival rate is 10%. According to Dipneo’s CEO, “improving this survival rate to 45% only requires being able to perform cardiopulmonary resuscitation satisfactorily as quickly as possible.”

Based in Barcelona, ​​Dipneo is formed by Xavier Castells, CEO, with senior experience as CFO and advisor in several companies and start-ups , as well as investor in start-ups in the health sector; and Julio Díaz, CTO, biomedical engineer with experience in resuscitation devices. It also has a committee of experts and the participation of Dr. Marc Bausili, specialist in anesthesiology and resuscitation and entrepreneur in this field, and David Osorio, director of the medical emergencies area of ​​the Red Cross in Catalonia.

__

(Featured image by yourschantz via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us